BMS’ Cell Therapy For Lymphoma On Track For EU-Wide Approval

Breyanzi’s EU Approval Will Introduce A Third CAR-T Therapy To The LBCL Market

 
• By Vibha Sharma

Several new drugs are now on track for an EU marketing authorization after getting the EMA’s thumbs up this week. 

gene therapy
Each dose of Breyanzi is created by collecting and genetically modifying a patient’s own immune cells to treat their cancer • Source: Alamy (Alamy Stock Photo)

More from Cell & Gene Therapies

More from Advanced Technologies